• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidine-2-ones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidones Pyrrolidine-2-ones
• Solvents and Organic Chemicals Organic Compounds Heterocyclic Compounds

Recent Advances in the Study of (4S)-4-hydroxypyrrolidin-2-one (CAS: 68108-18-9) in Chemical Biology and Pharmaceutical Research

The compound (4S)-4-hydroxypyrrolidin-2-one (CAS: 68108-18-9) has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This chiral building block is particularly valued for its role in the synthesis of bioactive molecules, including potential drug candidates. Recent studies have explored its utility in asymmetric synthesis, enzyme inhibition, and as a precursor for novel therapeutic agents. This research brief aims to summarize the latest findings and highlight emerging trends in the application of this compound.

One of the most notable advancements involves the use of (4S)-4-hydroxypyrrolidin-2-one as a key intermediate in the synthesis of gamma-aminobutyric acid (GABA) analogs. Researchers have demonstrated its efficacy in producing enantiomerically pure compounds that exhibit enhanced binding affinity to GABA receptors. These findings, published in the Journal of Medicinal Chemistry (2023), underscore the compound's potential in developing next-generation neuropharmaceuticals. The study employed a combination of computational modeling and experimental validation to optimize the synthetic pathway, achieving a yield of over 85% with high enantiomeric excess.

In addition to its role in neuropharmacology, (4S)-4-hydroxypyrrolidin-2-one has been investigated for its antimicrobial properties. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that derivatives of this compound exhibit potent activity against multidrug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, a mechanism distinct from traditional antibiotics. These findings open new avenues for addressing the global challenge of antibiotic resistance.

Another significant development is the application of (4S)-4-hydroxypyrrolidin-2-one in targeted drug delivery systems. A team at MIT recently developed a novel prodrug platform utilizing this compound as a linker, enabling site-specific release of anticancer agents. The system, described in Nature Biotechnology (2024), demonstrated enhanced tumor penetration and reduced off-target effects in preclinical models. This innovation represents a major step forward in precision medicine, with potential applications across multiple therapeutic areas.

From a chemical biology perspective, recent work has elucidated the compound's interactions with various enzymes. A 2023 study in ACS Chemical Biology revealed that (4S)-4-hydroxypyrrolidin-2-one serves as a competitive inhibitor for several hydrolases, providing insights into its metabolic fate and potential toxicity profiles. These findings are particularly relevant for drug development, as they inform the design of safer and more effective pharmaceutical compounds.

Looking ahead, the versatility of (4S)-4-hydroxypyrrolidin-2-one continues to inspire innovative research. Current investigations are exploring its use in peptide mimetics, biodegradable polymers, and as a scaffold for fragment-based drug discovery. The compound's unique stereochemistry and functional group compatibility make it an attractive candidate for diverse applications in medicinal chemistry. As research progresses, we anticipate further breakthroughs that will expand its utility in addressing unmet medical needs.

• 34368-52-0((3S)-3-hydroxypyrrolidin-2-one)
• 78340-48-4((S)-(-)-3-Hydroxy-2-pyrrolidone)
• 77510-50-0((3R)-3-hydroxypyrrolidin-2-one)
• 15116-68-4(3-Hydroxypyrrolidin-2-one)
• 15166-68-4(3-hydroxypyrrolidin-2-one)
• 25747-41-5(4-hydroxypyrrolidin-2-one)
• 22677-21-0((4R)-4-hydroxypyrrolidin-2-one)
• 96820-00-7(4-Hydroxy-2-pyrrolidone)
• 62624-29-7(4-hydroxypyrrolidin-2-one)
• 53598-98-4(4-Hydroxy-4-methylpyrrolidin-2-one)